Molecular brace traps two cancer-driving proteins and suppresses prostate cancer growth in preclinical tests
A novel therapeutic modality enforces non-native androgen receptor (AR)–p300/CBP interactions to collapse AR transcriptional programs, producing super-inhibitory, lineage-selective suppression of metastatic prostate cancer and establishing domain-alteration chimeras as a broadly applicable therapeutic strategy leveraging induced proximity.